{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Success rate was assessed as the number of participants with Multiple Myeloma (MM) who were first time mobilizers or unexposed to alkylating agents who completed the full course of filgrastim and desipramine and achieved the target collection of \\>=5 x 10\\^6 CD34+ cells/kg.","groups":[{"description":"Patients received 100mg desipramine hydrochloride PO daily from Day -3 to Day +4 (8 days total) and filgrastim PO BID from Day +1 to Day +4. Complete blood count (CBC) and peripheral blood CD34+ counts were determined on Day +4 and Day +5. Leukapheresis was started when peripheral blood CD34+ count exceeded 10/uL. If CD34+ counts were \\<10/uL on Day +5, plerixafor was added as a salvage therapy. Daily leukapheresis was performed with four times the estimated blood volume during each collection until a target cell dose of at least 5x10\\^6 cells/kg was reached. If the collected CD34+ cell dose was \\<0.5x10\\^6 on two consecutive days, apheresis was stopped and the patient was taken off study.\n\nDespiramine hydrochloride: PO Filgrastim: PO","id":"OG000","title":"Treatment (Desipramine, Filgrastim)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"6 participants underwent stem cell transplantation and completed the full study protocol.","reportingStatus":"POSTED","timeFrame":"Day 5","title":"Success Rate of Stem Cell Mobilization (SCM) in Participants Who Completed Filgrastim and Desipramine Therapy","type":"PRIMARY","unitOfMeasure":"Participants"}